Back
Sep 28
Education

EDU 11 - ASTRO/SNMMI Joint Session: Unlocking Success in Radiopharmaceutical Therapy: Collaboration between Radiation Oncology, Nuclear Medicine and Industry

04:45pm - 06:00pm PT
Professional Development/Medical Education/History

MODERATOR(S)

John Phillips, MD, MPH - Tennessee Oncology

session DESCRIPTION

Theranostics, a treatment paradigm pairing diagnostic molecular imaging with radiopharmaceutical therapy (RPT), is resurgent, mainly driven by the FDA approvals of 177Lu-dotatate for neuroendocrine tumors and 177Lu-PSMA-617 for prostate cancer. Novel RPTs are in development for every major cancer type, and the market projects that RPT will expand significantly. For example, PSMA-targeting RPT therapy has generated over $1 billion in revenue within just two years of being on the market. Despite this rapid growth, there has not been a corresponding surge in interest among our society members in delivering or developing these therapies. This session aims to share insights from providers who have successfully established and managed RPT programs in both academic and community settings, spanning the fields of Radiation Oncology and Nuclear Medicine. Panelists will discuss their experiences, including successes, challenges and common pitfalls to avoid. The panel will feature both community and academic Radiation Oncologists from ASTRO, as well as Nuclear Medicine Physicians representing SNMMI.

learning objectives

  1. Develop an understanding of what is needed in the clinic space for safe and compliant RPT delivery.
  2. Explain the current practice of modern RPTs and understand the framework for clinical implementation.
  3. Develop an understanding of the importance of patient selection and monitoring with molecular imaging.

Credits

AMA PRA Category 1 Credits: 1.25

Presentations